Rationale of combined modality therapy for cancer.
D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D000936:Antigen-Antibody Complex; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D003609:Dactinomycin / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D007700:Kinetics; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D014750:Vincristine / Q000627:therapeutic use; D009396:Wilms Tumor / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery
D000912:Antibodies, Neoplasm; D000936:Antigen-Antibody Complex; D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine